{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "G",
                    "alt": "S",
                    "position": "2019"
                },
                "variant_string_id": "LRRK2 G2019S"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkinson disease (PD) is a neurodegenerative movement disorder characterized by the selective loss of dopaminergic (DA) neurons in the substantia nigra pars compacta. LRRK2 mutations are a common genetic cause of parkinsonism, and disease - associated mutations of LRRK2 tend to increase its kinase activity and thereby its toxicity, though the exact mechanism is unclear.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly describes PD as a neurodegenerative disorder with selective DA neuron loss and mentions LRRK2 mutations as a cause, along with a proposed role of increased kinase activity in toxicity.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Transgenic Drosophila models were used to study the effects of LRRK2 variants. Immunohistochemistry was used to analyze DA neurons, climbing assays to assess locomotion, and rotenone treatment to test susceptibility to a PD - linked toxin. Co - expression of parkin was also examined for its neuroprotective effect.",
                    "judgment": "Yes",
                    "reasoning": "The use of Drosophila models, immunohistochemistry for analyzing DA neurons, climbing assays for locomotion related to DA function, and rotenone treatment to mimic PD - related stress all effectively model aspects of PD pathogenesis. Co - expression of parkin also relates to the disease mechanism as parkin has a role in PD.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Agematched normal flies were used as controls. The experiments were performed in triplicate (stated in the climbing assay section).",
                    "judgment": "Yes",
                    "reasoning": "Both normal controls (agematched normal flies) and replicates (performed in triplicate) were used in the climbing assay. This meets the criteria for basic controls and replicates in Step 3a.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "Wild - type LRRK2 - expressing flies were used as a control. There is no mention of known pathogenic or benign variants other than wild - type as controls, and no mention of variants reaching P/LP or B/LB criteria without relying on PS3/BS3 evidence.",
                    "judgment": "No",
                    "reasoning": "Only wild - type LRRK2 - expressing flies were used as controls, which does not meet the criteria of using known pathogenic or benign variants or variants with P/LP or B/LB classification without PS3/BS3 evidence.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for the LRRK2 G2019S variant is considered PS3_supporting. The disease mechanism of PD was defined, the assays used were applicable to the disease pathogenesis, basic controls and replicates were used, but no appropriate variant controls were present. So, the maximum strength of evidence is PS3_supporting."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "Y",
                    "alt": "C",
                    "position": "1699"
                },
                "variant_string_id": "LRRK2 Y1699C"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkinson disease (PD) is a neurodegenerative movement disorder characterized by the selective loss of dopaminergic (DA) neurons in the substantia nigra pars compacta. LRRK2 mutations are a common genetic cause of parkinsonism, and disease - associated mutations of LRRK2 tend to increase its kinase activity and thereby its toxicity, though the exact mechanism is unclear.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly describes PD as a neurodegenerative disorder with selective DA neuron loss and mentions LRRK2 mutations as a cause, along with a proposed role of increased kinase activity in toxicity.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Transgenic Drosophila models were used to study the effects of LRRK2 variants. Immunohistochemistry was used to analyze DA neurons, climbing assays to assess locomotion, and rotenone treatment to test susceptibility to a PD - linked toxin.",
                    "judgment": "Yes",
                    "reasoning": "The use of Drosophila models, immunohistochemistry for analyzing DA neurons, climbing assays for locomotion related to DA function, and rotenone treatment to mimic PD - related stress all effectively model aspects of PD pathogenesis.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Agematched normal flies were used as controls. The experiments were performed in triplicate (stated in the climbing assay section).",
                    "judgment": "Yes",
                    "reasoning": "Both normal controls (agematched normal flies) and replicates (performed in triplicate) were used in the climbing assay. This meets the criteria for basic controls and replicates in Step 3a.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "Wild - type LRRK2 - expressing flies were used as a control. There is no mention of known pathogenic or benign variants other than wild - type as controls, and no mention of variants reaching P/LP or B/LB criteria without relying on PS3/BS3 evidence.",
                    "judgment": "No",
                    "reasoning": "Only wild - type LRRK2 - expressing flies were used as controls, which does not meet the criteria of using known pathogenic or benign variants or variants with P/LP or B/LB classification without PS3/BS3 evidence.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for the LRRK2 Y1699C variant is considered PS3_supporting. The disease mechanism of PD was defined, the assays used were applicable to the disease pathogenesis, basic controls and replicates were used, but no appropriate variant controls were present. So, the maximum strength of evidence is PS3_supporting."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "G",
                    "alt": "R",
                    "position": "2385"
                },
                "variant_string_id": "LRRK2 G2385R"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Parkinson disease (PD) is a neurodegenerative movement disorder characterized by the selective loss of dopaminergic (DA) neurons in the substantia nigra pars compacta. LRRK2 mutations are a common genetic cause of parkinsonism, and disease - associated mutations of LRRK2 tend to increase its kinase activity and thereby its toxicity, though the exact mechanism is unclear.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly describes PD as a neurodegenerative disorder with selective DA neuron loss and mentions LRRK2 mutations as a cause, along with a proposed role of increased kinase activity in toxicity.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Transgenic Drosophila models were used to study the effects of LRRK2 variants. Immunohistochemistry was used to analyze DA neurons, climbing assays to assess locomotion, and rotenone treatment to test susceptibility to a PD - linked toxin.",
                    "judgment": "Yes",
                    "reasoning": "The use of Drosophila models, immunohistochemistry for analyzing DA neurons, climbing assays for locomotion related to DA function, and rotenone treatment to mimic PD - related stress all effectively model aspects of PD pathogenesis.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays",
                    "extracted_paper_info": "Agematched normal flies were used as controls. The experiments were performed in triplicate (stated in the climbing assay section).",
                    "judgment": "Yes",
                    "reasoning": "Both normal controls (agematched normal flies) and replicates (performed in triplicate) were used in the climbing assay. This meets the criteria for basic controls and replicates in Step 3a.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "Wild - type LRRK2 - expressing flies were used as a control. There is no mention of known pathogenic or benign variants other than wild - type as controls, and no mention of variants reaching P/LP or B/LB criteria without relying on PS3/BS3 evidence.",
                    "judgment": "No",
                    "reasoning": "Only wild - type LRRK2 - expressing flies were used as controls, which does not meet the criteria of using known pathogenic or benign variants or variants with P/LP or B/LB classification without PS3/BS3 evidence.",
                    "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for the LRRK2 G2385R variant is considered PS3_supporting. The disease mechanism of PD was defined, the assays used were applicable to the disease pathogenesis, basic controls and replicates were used, but no appropriate variant controls were present. So, the maximum strength of evidence is PS3_supporting."
        }
    ]
}